In Benjamin Ree's documentary, Steen's parents learn about their son's rich social life as an avid 'World of Warcraft' gamer ...

RBC Capital notes that Dyne Therapeutics (DYN) announced new clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients ...

Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics ...

Subscribe Login Register Log out My Profile Subscriber Services Search EBLADE ENTER-TO-WIN BLADE REWARDS BLADE VAULT / REPRINTS OBITUARIES JOBS CLASSIFIEDS BLADE HOMES HOMES WEEKLY ADS EVENTS ...

This year’s top stories on Duchenne muscular dystrophy (DMD) managed care included a novel imaging method for tracking disease progression, an FDA approval of the first nonsteroidal therapy ...

Living with Duchenne muscular dystrophy (DMD) has involved a series of challenges and triumphs, each shaping the person I am today. As 2025 approaches, I’m reflecting on that journey as well as ...

There are currently no approved treatments for Becker, although Santhera Pharmaceuticals has been evaluating its approved Duchenne muscular dystrophy corticosteroid Agamree in an FDA-funded phase ...

PTPN1/2 inhibition promotes muscle stem cell differentiation in Duchenne muscular dystrophy. Life Science Alliance , 2024; 8 (1): e202402831 DOI: 10.26508/lsa.202402831 Cite This Page : ...

A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration. McGill University researchers have discovered that an ...

Edgewise Therapeutics plans to meet with regulators in the U.S. and Europe to discuss how much clinical trial evidence it needs to seek expedited approval of its experimental drug for a form of ...

The company’s drug candidate, sevasemten, is used in the treatment of Becker muscular dystrophy and Duchenne muscular dystrophy. Sevasemten is an investigational orally administered small molecule ...